Journey Medical Corporation Announces Presentation Of Data From Phase 1 Clinical Trial Assessing The Impact Of DFD-29 On Microbial Flora Of Healthy Adults At 2024 AAD Annual Meeting; Clinical Trial Achieved All Three Primary Objectives And Subjects Completed 16-Week Treatment With No Significant Safety Issues

Saved in:
Bibliographic Details
Published inBenzinga Newswires
Format Newsletter
LanguageEnglish
Published Southfield Accretive Capital LLC d/b/a Benzinga 11.03.2024
Subjects
Clinical trials
Microbiota
Pharmaceutical industry
Rosacea
Skin
Vagina
Online AccessGet full text

Cover

More Information
Description not available.